Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: J Am Acad Dermatol. 2019 Feb 5;81(2):386–394. doi: 10.1016/j.jaad.2019.01.079

Figure 1. Receiver operator characteristic (ROC) curves for GenoMELPREDICT models.

Figure 1.

Comparison of the ROC curves derived from the (Figure 1a) 3-variable baseline GenoMELPREDICT model and MELPREDICT as reported by Niendorf et al., 2006; and (Figure 1b) 3-variable baseline GenoMELPREDICT model and the 4-variable GenoMELPREDICT model including any reported personal or family history of pancreatic cancer. Legend results are cross-validated areas under the curve (AUC) and 95% confidence intervals (CI) for GenoMELPREDICT models and AUC and 95% CI for MELPREDICT.